Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Fosfomycin | Research

High incidence of fosfomycin-resistant uropathogenic E. coli among children

Authors: Wedad M. Abdelraheem, W. K.M Mahdi, Ibtehal S. Abuelela, Noha Anwar Hassuna

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

There are few epidemiological or molecular data on Escherichia coli (E. coli) strains resistant to fosfomycin. In this study, we described the occurrence and characterization of fosfomycin-resistant uropathogenic E. coli (UPEC) isolated from children.

Materials and methods

This study was carried out on 96 E. coli isolates obtained from children with urinary tract infections. Two methods were performed to detect fosfomycin resistance: The agar dilution method and the rapid fosfomycin test. The disc diffusion method was done to detect the antimicrobial susceptibility pattern of all isolates. The phylogenetic grouping of all isolates was done according to the modified Clermont method. Conventional PCR was performed to detect plasmid-mediated fosfomycin-resistant genes (fos genes) and the blaCTX−M gene.

Results

Analyses of data were performed by SPSS software. A high percentage of fosfomycin resistance (37/96; 38.5%) was reported among UPEC isolates. The fosfomycin-resistant strains showed a higher resistance rate than fosfomycin-susceptible isolates to different antibiotics. E group (62.2%) was the most predominant phylogenetic group among the fosfomycin-resistant UPEC isolates, followed by Group B2 (21.6%) and group D (13.5%). The fos genes were detected in 21 isolates with the fosA3 gene as the most frequent, which was detected in 11 isolates followed by fosA (8), fosC2 (4), fosA4(1), and fosA5(1) genes.

Conclusion

This is the first report of a high prevalence of plasmid-mediated fosfomycin-resistant UPEC in Egypt. All of these isolates were multidrug-resistant to the tested antibiotics. Close monitoring of such strains is mandatory to prevent widespread dissemination of the genes code for antibiotic resistance.
Appendix
Available only for authorised users
Literature
1.
Shaikh N, Mattoo TK, Keren R, Ivanova A, Cui G, Moxey-Mims M, Majd M, Ziessman HA, Hoberman A. Early antibiotic treatment for Pediatric Febrile urinary tract infection and renal scarring. JAMA Pediatr. 2016;170(9):848–54.CrossRefPubMed
2.
Navidinia M, Peerayeh SN, Fallah F, Bakhshi B, Sajadinia RS. Phylogenetic grouping and pathotypic comparison of urine and fecal Escherichia coli isolates from children with urinary tract infection. Braz J Microbiol. 2014;45(2):509–14.CrossRefPubMedPubMedCentral
3.
Maczynska B, Frej-Madrzak M, Sarowska J, Woronowicz K, Choroszy-Krol I, Jama-Kmiecik A. Evolution of Antibiotic Resistance in Escherichia coli and Klebsiella pneumoniae clinical isolates in a Multi-Profile Hospital over 5 years (2017–2021). J Clin Med 2023, 12(6).
4.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious Diseases Society of America and the european Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–120.CrossRefPubMed
5.
Baquero-Artigao F, Del Rosal Rabes T. Fosfomycin in the pediatric setting: evidence and potential indications. Rev Esp Quimioter. 2019;32(Suppl 1):55–61.PubMedPubMedCentral
6.
7.
8.
Garcia-Fulgueiras V, Caiata L, Bado I, Giachetto G, Robino L. Antibiotic susceptibility and fosfomycin resistance characterization in a cohort of children older than 6 years of age with urinary tract infection. Rev Argent Microbiol. 2022;54(2):120–4.PubMed
9.
Loras C, Mendes AC, Peixe L, Novais A, Alos JI. Escherichia coli resistant to fosfomycin from urinary tract infections: detection of the fosA3 gene in Spain. J Glob Antimicrob Resist. 2020;21:414–6.CrossRefPubMed
10.
Cheesbrough M, Tropical Health T. District laboratory practice in tropical countries. 2nd ed. Cambridge: Cambridge University Press; 2005.CrossRef
11.
CLSI. : Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. Wayne, PA, USA: CLSI Supplement M100; Clinical and Laboratory Standards Institute. In.; 2020.
12.
Nordmann P, Poirel L, Mueller L. Rapid Detection of Fosfomycin Resistance in Escherichia coli. J Clin Microbiol 2019, 57(1).
13.
Sorlozano-Puerto A, Lopez-Machado I, Albertuz-Crespo M, Martinez-Gonzalez LJ, Gutierrez-Fernandez J. Characterization of Fosfomycin and Nitrofurantoin Resistance Mechanisms in Escherichia coli isolated in clinical urine samples. Antibiot (Basel) 2020, 9(9).
14.
Clermont O, Christenson JK, Denamur E, Gordon DM. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep. 2013;5(1):58–65.CrossRefPubMed
15.
Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z, Chen Z, Liu JH. Dissemination of the fosfomycin resistance gene fosA3 with CTX-M beta-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother. 2012;56(4):2135–8.CrossRefPubMedPubMedCentral
16.
Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother. 1997;40(3):393–9.CrossRefPubMed
17.
Benzerara Y, Gallah S, Hommeril B, Genel N, Decré D, Rottman M, Arlet G. Emergence of plasmid-mediated fosfomycin-resistance genes among Escherichia coli isolates, France. Emerg Infect Dis. 2017;23(9):1564.CrossRefPubMedPubMedCentral
18.
Saladin M, Cao VT, Lambert T, Donay JL, Herrmann JL, Ould-Hocine Z, Verdet C, Delisle F, Philippon A, Arlet G. Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three parisian hospitals. FEMS Microbiol Lett. 2002;209(2):161–8.PubMed
19.
Amin EK, Kotb AERI. Epidemiology of urinary tract infections in the children in zagazig university children’s hospital. Zagazig Univ Med J. 2019;25(6):909–18.CrossRef
20.
Lu J, Wang L, Wei Y, Wu S, Wei G. Trends and risk factors of extended-spectrum beta-lactamase urinary tract infection in chinese children: a nomogram is built and urologist should act in time. Translational Pediatr. 2022;11(6):859.CrossRef
21.
El-Gamasy M, Fakhreldin A. Urine screening for a sample of egyptian school students: two centers experience. Int J Fam Commun Med. 2018;2:00031.
22.
Lehrasab W, Aziz T, Naheem Ahmed IA. Causative organisms of urinary tract infection and their sensitivity pattern in children. Annals of PIMS ISSN. 2016;1815:2287.
23.
Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martinez-Ruiz R, Perez-Vazquez M, Alcaraz M, Garcia-Cobos S, Campos J. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother. 2009;64(4):712–7.CrossRefPubMed
24.
Rodríguez-Lozano J, de Malet A, Cano ME, de la Rubia L, Wallmann R, Martínez-Martínez L, Calvo J. Antimicrobial susceptibility of microorganisms that cause urinary tract infections in pediatric patients. Enferm Infecc Microbiol Clin. 2018;36(7):417–22.CrossRef
25.
Mueller L, Cimen C, Poirel L, Descombes M-C, Nordmann P. Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland. Eur J Clin Microbiol Infect Dis. 2019;38:945–9.CrossRefPubMed
26.
Mosime LB, Newton-Foot M, Nel P. Fosfomycin resistance in community-acquired urinary pathogens from western Cape, South Africa. South Afr J Infect Dis. 2022;37(1):321.
27.
Ali I, Rafaque Z, Ahmed S, Malik S, Dasti JI. Prevalence of multi-drug resistant uropathogenic Escherichia coli in Potohar region of Pakistan. Asian Pac J Trop Biomed. 2016;6(1):60–6.CrossRef
28.
El-Wafa MA, Abouwarda W. In vitro assessment of the antibacterial effects of the combinations of fosfomycin, colistin, trimethoprim and nitrofurantoin against multi‐drug–resistant Escherichia coli. Lett Appl Microbiol. 2022;74(3):334–43.CrossRef
29.
Lee H, Le JP. BOOK 1 Urinary tract infections. In.: PSAP; 2018.
30.
Hassuna NA, Khairalla AS, Farahat EM, Hammad AM, Abdel-Fattah M. Molecular characterization of extended-spectrum β lactamase-producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt. Sci Rep. 2020;10(1):1–8.CrossRef
31.
Gad AH. The occurrence of Multidrug Resistant E. Coli which produce ESBL and cause urinary tract infections. J Appl Microbiol. 2017;1(2):8.
32.
Tharwat N, El-Sherif R, Elnagdy S, Marzaban R, Amer S. Virulent Escherichia coli strains among egyptian patients with acute diarrhoea versus urinary tract infection, and their antibiotic susceptibility. Arab J Gastroenterol. 2019;20(2):74–80.CrossRefPubMed
33.
Masoud SM, Abd El-Baky RM, Aly SA, Ibrahem RA. Co-existence of certain ESBLs, MBLs and plasmid mediated quinolone resistance genes among MDR E. coli isolated from different clinical specimens in Egypt. Antibiotics. 2021;10(7):835.CrossRefPubMedPubMedCentral
34.
Li Y, Zheng B, Li Y, Zhu S, Xue F, Liu J. Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China. PLoS ONE. 2015;10(8):e0135269.CrossRefPubMedPubMedCentral
35.
El-Baz R, Said HS, Abdelmegeed ES, Barwa R. Characterization of virulence determinants and phylogenetic background of multiple and extensively drug resistant Escherichia coli isolated from different clinical sources in Egypt. Appl Microbiol Biotechnol. 2022;106(3):1279–98.CrossRefPubMedPubMedCentral
36.
Čurová K, Slebodníková R, Kmeťová M, Hrabovský V, Maruniak M, Liptáková E, Siegfried L. Virulence, phylogenetic background and antimicrobial resistance in Escherichia coli associated with extraintestinal infections. J Infect Public Health. 2020;13(10):1537–43.CrossRefPubMed
37.
Dadi BR, Abebe T, Zhang L, Mihret A, Abebe W, Amogne W. Distribution of virulence genes and phylogenetics of uropathogenic Escherichia coli among urinary tract infection patients in Addis Ababa, Ethiopia. BMC Infect Dis. 2020;20:1–12.CrossRef
38.
Yılmaz E, Aslantaş Ö. Phylogenetic group/subgroups distributions, virulence factors, and antimicrobial susceptibility of Escherichia coli strains from urinary tract infections in Hatay. Rev Soc Bras Med Trop 2020, 53.
39.
Clermont O, Condamine B, Dion S, Gordon DM, Denamur E. The E phylogroup of Escherichia coli is highly diverse and mimics the whole E. coli species population structure. Environ Microbiol. 2021;23(11):7139–51.CrossRefPubMed
40.
Wachino J-i, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother. 2010;54(7):3061–4.CrossRefPubMedPubMedCentral
41.
Sato N, Kawamura K, Nakane K, Wachino J-I, Arakawa Y. First detection of fosfomycin resistance gene fosA3 in CTX-M-producing Escherichia coli isolates from healthy individuals in Japan. Microb Drug Resist. 2013;19(6):477–82.CrossRefPubMed
42.
Cao X-L, Shen H, Xu Y-Y, Xu X-J, Zhang Z-F, Cheng L, Chen J-H, Arakawa Y. High prevalence of fosfomycin resistance gene fosA3 in blaCTX-M-harbouring Escherichia coli from urine in a chinese tertiary hospital during 2010–2014. Epidemiol Infect. 2017;145(4):818–24.CrossRefPubMed
Metadata
Title
High incidence of fosfomycin-resistant uropathogenic E. coli among children
Authors
Wedad M. Abdelraheem
W. K.M Mahdi
Ibtehal S. Abuelela
Noha Anwar Hassuna
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08449-9

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue

Research

Monkeypox detection using deep neural networks

Research

Clinical features and severe outcome predictors of COVID-19 vaccine breakthrough infection among hospitalized patients: results from Egypt severe acute respiratory infections sentinel surveillance, 2021–2022

Research

Clinical characteristics and prognostic nomograms of 12555 non-severe COVID-19 cases with Omicron infection in Shanghai

Case Report

Skin lesions by Scedosporium apiospermum and Nocardia pulmonary infection in an oncologic patient: a case report

Research

Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study

Research

Characteristics and outcomes in adult patients with Staphylococcus lugdunensis bacteremia compared to patients with Staphylococcus epidermidis and Staphylococcus aureus bacteremia: a retrospective study in a 16-year period at the university hospital, Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits